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Introduction
The vitamin D receptor (VDR) binds the active form of vitamin D (1,25-dihydroxyvitamin
D3). It belongs to the family of trans-acting transcriptional regulatory factors and shows
sequence similarity to the steroid and thyroid hormone receptors. The gene was cloned by
Baker and colleagues in 1988 and maps to chromosome 12q13.11 [1]. It consists of nine
exons with at least six isoforms of exon 1, spans 63.5 kb, and encodes a 427 amino acid
protein [2]. Alternative splicing results in multiple transcript variants encoding the VDR
protein of different lengths [3,4].
The interaction of 1,25-dihydroxyvitamin D3 with VDR modulates many biological
activities of the neural, immune, and endocrine systems, including calcium and phosphorous
homeostasis, apoptosis, and cell differentiation (reviewed by Hewison and colleagues [5-7]).
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Its pleiotropic property is reflected by the findings that VDR is expressed in at least 37
tissues, which can roughly be grouped into seven biological systems (calcium homeostasis,
immune, pancreatic β cells, muscle, cardiovascular, brain, and lung) [8-10]. The most
characterized mechanism is the binding of vitamin D3 to nuclear VDR, which activates the
receptor to form a heterodimer with the retinoid-X receptor and interacts with a specific
DNA sequence on the gene promoter regions called the ‘vitamin D response element’
(VDRE). Transcription repressors occupying the VDRE are then replaced by transcription
activators to initiate transcription of targeted genes. Microarray analyses using different
human cell lines have identified over 100 genes with VDREs in the promoter regions, all
potential targets of the 1,25-dihydroxyvitamin D3–VDR complex [11-13]. In human oral
squamous carcinoma SCC25 cells, genes with characterized VDREs and of which
demonstrated greater than 10-fold increase after treatment with 1,25-dihydroxy-vitamin D3
include 24-hydroxylase (CYP24), 17β-hydroxy-steroid dehydrogenase (HSD17B2), CD14
(CD14), type XIII collagen (COL13A1), and 5-lipoxygenase (ALOX5) [13]. The effect of
1,25-dihydroxyvitamin D3 by binding to VDR in the nucleus is often described as the slow-
acting genomic effect; the effect will take days or hours to be noticed.
Alternatively, 1,25-dihydroxyvitamin D3 can bind to VDR located in the caveolae in the
plasma membrane to exert rapid responses through production of second messengers [14].
Pathways that have been shown to be activated by the 1,25-dihydroxyvitamin D3–
VDR[memb] complex include mitogen-activated protein kinase-dependent [15], cAMP-
dependent [16], phospholipase A2-dependent [17], phospholipase C-dependent [18],
phosphatidylinositol 3-kinase-dependent [19], and protein kinase C-dependent [20]
pathways. Examples of such rapid response include rapid Ca2+ absorption in the duodenum
[21,22], opening of Cl− channels and secretion in osteoblasts, insulin secretion from
pancreatic β-cells [23,24], and vascular smooth muscle cell migration [19].
VDR variations
Because of the pleiotropic effect exerted by the 1,25-dihydroxyvitamin D3–VDR complex,
its genetic variants have been found to be associated with a wide variety of diseases/
phenotypes, including various types of cancer, tuberculosis, asthma, height, longevity/
mortality, insulin-dependent diabetes mellitus, bone mineral density (BMD), and
hyperparathyroidism, as reviewed comprehensively elsewhere [25,26]. This study focuses
on clinically relevant associations between treatment responses in the presence of VDR
genetic polymorphisms. Furthermore, although no VDR polymorphism has been reported to
be associated with vitamin D treatment in cancer therapy, the findings that VDR expression
is reduced in colon cancer and negatively correlated with progression imply a role of VDR
protein expression in treatment response [27-29].
In a comprehensive study of the genetic architecture of VDR, areas of low linkage
disequilibrium (LD) and areas of high LD were observed [30]. This study further noted that
the number and size of LD blocks are different in whites, Han Chinese, and Africans. In
whites, four blocks were found at the 5′ end, and the largest block encompassed exons 4–9
and 3′ UTR. The LD structure in Han Chinese is similar to that of whites but that of African
Americans is substantially fragmented and different from that of whites and Han Chinese.
The 5′ promoter variants Cdx2 and GATA reside in block 2, and the three widely studied 3′
variants BsmI, ApaI, and TaqI are located in block 5; variant FokI does not reside in any
block and is located between blocks 2 and 3. However, further analysis of this genomic area
showed that the three variants do not capture all the information in the block [31]. (Note: In
the nomenclature of the variants, the alleles are conventionally defined by capital letters in
the absence of a restriction site and by small letters in the presence of a given restriction site;
for example, TaqI T and C alleles are named T and t, respectively. To avoid confusion this
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review will only use the allele corresponding to the nucleic acid.) This review highlights the
pharmacogenetic effects of VDR polymorphisms in various biological systems. Table 1
summarizes the functional effect and associated phenotypes of genetic variants in the VDR
gene.
Important variants
5′ variants
VDR: rs11568820 (A > G, commonly known as Cdx2) and rs4516035 (T > C,
commonly known as GATA)—Two functional variants lying in an LD block in the
promoter region captured the genetic information around exons 1e and 1a and are often
analyzed as a haplotype block [51]. These two variants are commonly known as Cdx2
(rs11568820) and GATA (rs4516035). Variant rs11568820 resides in the binding site of
transcription factor Cdx2, upstream of exon 1e. Functional analyses showed that the A to G
base substitution (referring to the minus strand) eliminates the Cdx binding site and reduces
transcriptional activity of VDR to 70% of the A allele [52,53]. The frequency of allele A
ranges from 50% in Asians to 80% in Europeans to 98% in Sub-Saharan Africans, as
estimated by the HapMap Project [54]. Downstream is variant rs4516035, which resides at
the GATA binding site, and its C allele eliminates the GATA binding site and confers a
lower VDR promoter activity [51]. The frequency of allele T ranges from 50% in Europeans
to 98% in Asians to 99% in Sub-Saharan Africans [54]. Allele Tof GATA is found to have a
1.9-fold higher VDR promoter activity compared with allele C [51]. In a study on 69 Dutch
children with acute lymphoblastic leukemia, the effect of dexamethasone treatment on body
composition was investigated. It was found that, during treatment, noncarriers of haplotype
Cdx2 allele A/GATA allele C had greater fat gain and higher BMD and apparent BMD of
the lumbar spine compared with the carriers [32]. In another study that examined the effect
of VDR polymorphisms on growth and treatment response of 1α-hydroxyvitamin D3
derivatives, vitamin D3, and phosphates to X-linked hypophosphatemic rickets, patients who
were treated with 1α-hydroxyvitamin D3 since childhood experienced less growth defect
compared with those not treated with 1α-hydroxyvitamin D3 [33]. When the Cdx2/GATA
haplotypes of these patients were considered, patients who had been treated with 1α-
hydroxyvitamin D3 since childhood and were carriers of Cdx2 G/GATA C haplotype
experienced less growth defect compared with noncarriers. In children receiving 1α-
hydroxyvitamin D3 and who were carriers of Cdx2 G/GATA C haplotype, a lower urinary
calcium/creatinine level was detected compared with noncarriers, suggesting that Cdx2 G/
GATA C may protect these children from developing hypercalciuria during treatment.
Taken together, these studies showed that carriers of Cdx2 G/GATA C and Cdx2 G/GATA
T haplotypes were at lower risk of having bone-related side effects from treatment with 1α-
hydroxyvitamin D3 and dexamethasone.
In a recent study that examined the effect of VDR genotypes, calcium intake, and prostate
cancer in African Americans, carriers of the Cdx2 GG genotype were found to be at a lower
risk (roughly 40% of men of AA genotype) of developing advanced cancer, and such risk
was further reduced (8% of men of AA genotype) when coupled with a low-calcium diet
[34]. The authors noted that the same association was not observed with localized prostate
cancer, suggesting that high calcium intake is not involved in the initiation but progression
of prostate cancer.
VDR: rs2228570 (T > C, commonly known as FokI)—At the translation start site of
VDR, a T > C base change of variant rs2228570 eliminates the translation start site in exon
2, and the encoded protein is shortened by three amino acids [55]. The frequency of allele T
ranges from 40% in whites and Asians to 20% in Sub-Saharan Africans [54]. The smaller
protein exhibits greater transcription activity because of its greater binding efficiency to
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transcription factor IIB [56]. In immune cells, transcripts with the C allele (often referred to
as allele F of FokI polymorphism) demonstrated stronger transcriptional effect of VDR
target genes [57]. Given the pivotal role of 1,25-dihydroxyvitamin D3 and calcium
absorption, variant FokI has been studied for its association with calcium absorption, BMD,
and other anthropometric measures. In an association study of calcium absorption kinetics,
bone mineralization rates, and VDR polymorphisms in early pubertal adolescents,
individuals with the TT genotype had less total calcium absorption, and less calcium
accretion to the skeleton [36]. In an earlier study, children with the TT genotype were found
to have lower calcium absorption and lower BMD, after adjusting for age, ethnicity, BMI,
and puberty status [37]. In a study on 36 white postmenopausal women with osteoporosis or
osteopenia who were treated with calcium and vitamin D supplements for 3 months, the
FokI TC genotype was more common in responders compared with nonresponders [38].
In a study that examined the genotypic effect of VDR polymorphism and calcipotriol
response in white psoriasis patients, variant FokI alone was not associated with any
significant effect; however, when analyzed in combination with variant Cdx2, patients with
the Cdx2 AA/FokI CC genotype combination were four times more likely to respond to
calcipotriol [35]. Furthermore, additional variant combinations found to be associated with
calcipotriol response were Cdx2 AA/TaqI TT and FokI CC/TaqI TT. A similar association
with positive response to calcipotriol in psoriasis patients was detected in a Turkish
population [42].
In a study that examined the VDR genetic effect on treatment response of antimycobacterial
chemotherapy against tuberculosis in Peruvian patients, carriers of the FokI CC genotype
had faster conversion of sputum mycobacterial culture from positive to negative compared
with non-CC genotype carriers [39].
In an in-vitro study on thyroid cancer, thyroid cancer cell lines that had significant decrease
in cell viability after VDR agonist treatment were found to be those carrying the FokI TT
genotype, whereas those of CC genotype were resistant [40]. Further analysis of the mRNA
level of 1α-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24A1) suggested that the C
allele may confer resistance by upregulation of 24-hydroxylase and subsequent suppression
on VDR activation. However, in an in-vitro study on breast cancer, carriers of the CC
genotype were found to have the greatest growth inhibition compared with the TT genotype
and vector control after treatment with 1,25-dihydroxy-vitamin D3 [41]. VDR protein level
was found to be elevated in the CC, TT genotype carriers and vector control, with CC
genotype carriers exhibiting the highest elevation. CYP24A1, a downstream target gene,
was upregulated at both the mRNA and protein levels after 1,25-dihydroxyvitamin D3
treatment, with the CC genotype carriers exhibiting the greatest elevation. In contrast, the
protein level of another downstream target, estrogen receptor α (ESR1), was downregulated
after treatment, and cells with the CC genotype exhibited the greatest protein suppression.
Furthermore, estrogen-induced cell growth was inhibited by 1,25-dihydroxyvitamin D3 in
the cells with the CC genotype but not in the TT genotype counterparts. In the same study
the authors demonstrated greater VDR protein stability and longer half-life after 1,25-
dihydroxy-vitamin D3 treatment in cells carrying the CC genotype compared with vector
control and the TT counterparts.
3′ variants
VDR: rs1544410 (C > T, commonly known as BsmI)—This variant is commonly
known as BsmI and is located in intron 8 (allele C is commonly referred to as allele b and
allele T is referred as allele B). No known functional consequence of this variant has been
described; however, a few studies have found that it is associated with antiresorptive
treatment responses [40,41,47,48]. In a study on the effectiveness of antiresorptive treatment
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in postmenopausal women, treatment outcomes (i.e. BMD, bone formation and bone
resorption) were found to be influenced by treatment arms, genotype at variant BsmI and
treatment arms × genotype interactions [47]. Women with the CC genotype had greater
improvement in BMD after treatment compared with those with the TT genotype, regardless
of the treatment arms. Decrease in bone formation after treatment was the least in CC
women compared with their CTand TTcounterparts. Homozygous CC women also
demonstrated the least decrease in bone resorption compared with the other two genotype
groups. In a pilot study on antiresorptive treatment (oral alendronate vs. subcutaneous
teriparatide) in postmenopausal women, women who received alendronate and had at least
one allele C had greater BMD at their lumbar spine compared with those with the TT
genotype [48]. In addition to a genotypic effect toward antiresorptive treatment, BsmI is also
associated with response to calcium and vitamin D supplementation in healthy adolescent
girls [58]. In a study on 167 adolescent girls from Lebanon, placebo and vitamin D
supplements were given randomly for a year, and bone mineral content (BMC), BMD, and
lean mass were measured as outcomes [45]. In the treatment group, percentage change in
BMC of the total body, hip, and trochanter were significantly greater in CT heterozygous
individuals compared with CT nontreated controls. A similar trend was observed in CC
girls, although it did not reach statistical significance. In a study that investigated the effect
of longterm antiepileptic treatment on BMD in men and premenopausal women, those with
the CC genotypes had higher BMD, higher serum level of 25-hydroxyvitamin D3, and lower
level of parathormone, compared with those with the CT and TT genotypes [49].
VDR: rs7975232 (C > A, commonly known as ApaI)—This variant is commonly
known as ApaI and is located in intron 8 (allele A is often referred to as allele A and allele C
is allele a). At present, no known functional consequence of this variant has been described.
In a study that investigated the effect of dairy intake and colorectal cancer recurrence, an
interaction between ApaI genotype and dairy product intake was detected [50]. In particular,
individuals with at least one copy of allele A and who consumed a large amount of dairy
products had the lowest risk of colorectral cancer recurrence compared with CC genotype
carriers who consumed lower amounts of dairy products.
VDR: rs731236 (T > C, commonly known as TaqI)—This variant is commonly
known as TaqI and is located in exon 9 (allele T is often referred to as allele T, and allele C
is allele t). In a study on tuberculosis susceptibility, it has been demonstrated in
lymphoblastoid cell lines that this variant resides on a CpG island and the C allele is always
methylated, and that interactions exist between TaqI polymorphism, methylation levels,
ethnicities, and tuberculosis susceptibility [43].
In a multivariate study investigating the interaction between therapy and VDR variants,
allele C confers increased risk to new fracture in postmenopausal women treated with
calcium supplement in Australia [44]. Healthy adolescent girls with the TT genotype had
greater spine and femoral neck BMC and femoral neck area when given vitamin D
supplement, compared with the CC group [45]. In a study using narrowband ultraviolet light
to treat chronic plaque psoriasis, individuals with the CC genotype had the shortest
remission period compared with the other genotypes [46]. In another study that examined
the VDR genetic effect on treatment response of antimycobacterial chemotherapy against
tuberculosis in Peruvian patients, variant FokI CC and TaqI CT genotypes were both found
to be associated with faster conversion of sputum mycobacterial culture from positive to
negative [39].
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Conclusion
The pleiotropic effects of 1,25-dihydroxyvitamin D3 on a wide range of physiological
systems render its receptor VDR an attractive candidate for investigation in disease
mechanism and therapeutic responses. Of the six conventionally investigated variants, those
at the 5′ end have the biological consequence of the base change characterized. Recently,
the biological effect of the base change at the TaqI variant was also characterized as
aforementioned. It is likely that the associations observed for variants BsmI and ApaI are
due to linkage disequilibrium with the causative variant(s). Given the vast number of genes
whose transcription can be upregulated or downregulated by VDR, an allele may be a risk
factor for one trait and a protective one for another. Although the scientific community
agrees that the present guidelines for vitamin D intake must be augmented, one must take
into account the differential activity of the VDR protein as partially dictated by variations in
the VDR gene.
This PharmGKB summary briefly discusses the very important pharmacogene VDR and its
variants that can influence drug responses. A fully interactive version of this short review,
with links to individual paper and detailed mapping information, can be found at http://
www.pharmgkb.org/search/annotatedGene/vdr/index.jsp.
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Table 1
The functional effect and associated phenotype of genetic variants in the VDR gene
SNP Functional consequence Medical condition Treatment Associated phenotypes
rs11568820 A >G eliminates Cdx
 binding site
Childhood acute lymphoblastic
 leukemia
Dexamethasone Fat gain, BMD, and apparent
BMD of the lumbar
 spine [32]
X-linked hypophosphatemic ricket
 patients
1α-Hydroxyvitamin D3 Growth defect and urinary
calcium/keratinise
 levels [33]
Prostate cancer risk Low-calcium diet Prostate cancer risk [34]
Psoriasis Calcipotriol Calcipotriol response [35]
rs4516035 T>C eliminates GATA
 binding site
Childhood acute lymphoblastic
 leukemia
Dexamethasone Fat gain, BMD and apparent
BMD [32]
X-linked hypophosphatemic
 ricket patients
1α-Hydroxyvitamin D3 Growth defect and urinary
calcium/keratinise
 levels [33]
rs2228570 T>C eliminates
translation
 start site
Puberty Not applicable Calcium absorption and
calcium accretion to
 skeleton [36]
Childhood Not applicable Calcium absorption and BMD
[37]
Osteoporosis or osteopenia Calcium and vitamin D Vitamin D and parathyroid
hormone levels [38]
Psoriasis Calcipotriol Calcipotriol response [35]
Tuberculosis Antimycobacterial
 chemotherapy
Sputum mycobacterial culture
conversion [39]
Thyroid cancer VDR agonist Cell viability [40]
Breast cancer 1,25-Dihydroxyvitamin D3 Growth inhibition [41]
rs731236 T>C methylation site Psoriasis Calcipotriol Calcipotriol response [42]
Tuberculosis Not applicable Tuberculosis susceptibility [43]
Postmenopausal women Calcium supplement New fracture [44]
Adolescent girls Vitamin D supplement Spine and femoral neck BMC
and femoral neck
 area [45]
Chronic plaque psoriasis Narrowband ultraviolet
 light
Remission period [46]
rs1544410 C>T, unknown functional
 consequence
Postmenopausal women Antiresorptive treatment BMD, bone formation and
bone resorption [47]
Postmenopausal women Antisorptive treatment BMD [48]
Adolescent girls Vitamin D supplement BMC [45]
Epilesy Antiepileptic treatment BMD, serum 25-
hydroxyvitamin D3 level and
 parathormone level [49]
rs7975232 C>A, unknown functional
 consequence
Colorectal cancer Dairy product intake Colorectal cancer recurrence
[50]
BMD, bone mineral density; SNP, single nucleotide polymorphism; VDR, vitamin D receptor.
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